Blocking of IL-17A signaling using an antibody against IL-17A ameliorated liver injury and HCC development; hence, IL-17A may serve as a valuable non-invasive marker for insulin resistance and the pathogenesis of MASH in obese patients (Gomes et al., 2016). The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatohepatitis.